Eli Lilly’s experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an average 12% body weight loss in a Phase 3 trial. The study, involving overweight or obese adults, revealed significant weight reduction and improved cardiovascular markers. Post navigation Jibe, ouster & quick U-turn: K’taka minister now backs Rahul’s ‘vote theft’ claim ‘Countering terrorism’: US designates BLA terror outfit; decision after Asim Munir’s visit
